TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Test for the Treatment of Multifocal Lung Cancers Using Genome Sequencing

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subject must be \> 18 years of age~* Presumed or known lung cancer.~* Undergoing bronchoscopy, CT guided lung biopsy, or lung resection as part of their clinical care at the Mayo Clinic Rochester.~* PFT's and other clinical determinates that show the subject is capable of tolerating a lung biopsy or resection.~* Non-pregnant and non-lactating. Women of child-bearing potential must have a negative urine or serum pregnancy test to participate in the study.~* Subject must be able to understand and willing to sign an IRB-approved informed consent document.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Autologous Hematopoietic Stem Cell Transplant in Neuromyelitis Optica

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age between 18-65, inclusive~* Diagnosis of NMO using Wingerchuk 2006 NMO Criteria~* EDSS 0-6.5~* Treatment with a minimum of one NMO therapy in past 12 months~* One objective and documented relapse in the past 12 months and two relapse events in the past 24 months despite medical therapy~* ECOG performance status 0-3~* Platelets ≥100 x 109/L~* ALT ≤3 x ULN~* Total bilirubin ≤2.0 x ULN, except in patients with Gilbert syndrome or in patients in whom the bilirubin rise is of non-hepatic origin~* Serum creatinine \<1.5 x ULN or creatinine clearance ≥50 cc/min~* Patients must reside in Alberta, Canada for the duration of the transplant period of the trial~Exclusion Criteria:~* Any illness that would jeopardize the ability of the patient to complete study protocol~* Prior malignancy unless non-melanoma skin cancer, carcinoma in-situ of the cervix (CIN) or breast, or malignancy treated more than 5 years previously with no evidence of recurrent disease since initial treatment~* Pregnant or lactating females. Women of childbearing potential must have a negative serum or urine β-hCG pregnancy test at screening~* Inability or unwillingness to pursue effective means of birth control~* FEV1/FVC \< 50% of predicted~* DLCO \< 50% of predicted~* Resting LVEF \< 50 %~* Known hypersensitivity to mouse, rabbit, or E. Coli derived proteins, or to iron compounds/medications~* Presence of metallic objects implanted in the body that would preclude the ability of the patient to safely have MRI exams~* Unable or unwilling to provide written informed consent for participation~* Active infection except asymptomatic bacteriuria~* Any use of investigational therapies within 4 weeks prior to initiation of study treatment~* Patients dependent on prednisone who cannot be successfully tapered to a maximum of 0.5mg/kg/d prior to mobilization therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- AHSCT (Type: EXPERIMENTAL): All patients undergo autologous hematopoietic stem cell transplantation in a two stage process.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Thoracal Radiotherapy and Tarceva

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \>18 years~* Histological or cytological verified NSCLC~* Palliative radiotherapy to thorax indicated~* ECOG Performance status 0-2~* Fertile patients must use contraception~* Signed informed consent~* Ability to understand and fill in QoL questionnaires~* Capability to take per os medication~* Serum bilirubin \< 2 times upper limit of normal (ULN)~* AST and ALT \< 2 times ULN (\< 5 times ULN if liver metastases are present)~* Creatinine \< 5 times ULN~Exclusion Criteria:~* Pregnancy or nursing~* Other prior or concurrent malignant disease likely to interfere with study treatment or comparisons~* No evidence of other significant laboratory finding or concurrent uncontrolled medical illness, that in the opinion of the investigator, would interfere with study treatment or results comparison or render the patient at high risk for treatment complications~* No prior radiotherapy to the same organ / place~* No concurrent treatment with other experimental drugs~* Known brain metastases in need of radiotherapy~* Known hypersensitivity to erlotinib or other substances in the erlotinib tablets.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Radiotherapy combined with erlotinib (Type: EXPERIMENTAL): Standard treatment 3 Gy x 10 to lung tumor and mediastinal lymph nodes and erlotinib given concomitantly, 150 mg p.o. daily from the day before radiation, until the last day of radiation.
- Radiotherapy alone (Type: ACTIVE_COMPARATOR): Radiotherapy 3 Gy x 10 alone

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Exercise and Counseling Intervention on Relapse in Smoker With Depressive Disorders

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Ages 18 to 65 years~* Must be able to give informed consent~* Must live in the area for the next 3 months~* Depression subscale of the Hospital Anxiety and Depression Scale, HADS-D score ≥ 8~* Fagerstrom score \> 3~* Must be sedentary, have not participated regularly in aerobic physical exercise (for at least 20 minutes per day, 3 days per week) for the past six months.~* Must be able to exercise at 60% maximum heart rate (MHR) (cleared by a physician)~Exclusion Criteria:~* Cannot read or write fluently in the French language~* Pregnancy or plans to attempt pregnancy~* 60 minutes or more per week of moderate or vigorous physical activity~* Currently in a quit smoking program~* Currently using NRT of any kind or using any other quit smoking method or treatment~* Poor willingness or inability to comply with protocol requirements~Medical problems:~* Cancer treatment within the past 6 monthsPsychiatric Problems~* Currently suicidal or psychotic, (or suicidal/psychotic in last 6 months)~* Taking these specific medications for psychiatric problems: Mood stabilizer (Lithium, Depakote, Neurontin), Antipsychotics (Haldol, Clozaril, Risperdal)~* Currently diagnosis of a bipolar disorder as assessed by MINI 5.0~* Currently diagnosis of a alcohol dependence as assessed by MINI 5.0

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Control (Type: ACTIVE_COMPARATOR): All subjects (intervention and control groups) participate in a smoking cessation program composed of a pharmacological treatment (including nicotine replacement therapy or varenicline) and counseling.
- physical activity program (Type: EXPERIMENTAL): Experimental group subjects were required to attend 2 supervised exercise sessions and 2 counseling sessions during Week 1 and Week 2. Supervised exercise and counseling sessions are realized successively. For Week 3 to 8, participants were required to attend 1 supervised exercise session and 1 counseling session plus 1 home exercise session.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Noise-Induced Hearing Loss-Acute Exposure Treatment (UA)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Screening Inclusion Criteria:~* Police officers who are scheduled for firearm training and/or certification on the range.~* At least 18 years of age.~* Air conduction thresholds are to be no worse than 25 dB HL from 0.5 kHz to 3 kHz, no worse than 30 dB HL at 4 kHz, and no worse than 45 dB HL at 6 and 8 kHz prior to shooting range exposure.~* Ability to understand and willingness to sign an IRB approved written informed consent document.~Enrollment Inclusion Criteria:~* Observed audiometric TTS ≥ 10 dB HL at 2, 3, 4 and/or 6 kHz~* Observed air-bone gap \< 10 dB HL at .5, 1, 2 and 4 kHz, with normal tympanometry~Exclusion Criteria:~* History of known sulfa allergy or hypersensitivity to carbonic anhydrase inhibitors.~* History of moderate-to-severe kidney or liver disease.~* Acute viral, bacterial, fungal or parasitic infection.~* History of seizures.~* Currently pregnant or breast-feeding.~* Any current or history of otologic disorder.~* History of ototoxic drug use.~* Current use of strong/moderate 3A4 inhibitor/inducer and grapefruit juice.~* For secondary outcomes, exclusion criteria is as follows:~  1. DPOAE data will be used as a secondary outcome measure of TTS, and participants will be excluded if their DPOAE is absent at more than 3/7 frequencies. Criteria for a present response is any response that is \> 5 dB SPL above the noise floor and replicable within ±5 dB SPL.~ 2. ECochG: Participants will be excluded if the ECochG/ABR wave I response is absent.~ 3. WIN test: Participants with WIN scores greater than moderate difficulty or 14.9 dB SNR will be excluded.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Zonisamide (Type: EXPERIMENTAL): For subjects randomized to zonisamide, the package will contain one zonisamide capsule (100 mg PO).
- Placebo (Type: PLACEBO_COMPARATOR): For the subjects randomized to placebo, the package will contain one placebo capsule that looks, smells, and taste the same as zonisamide capsule.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Sedation Strategies for Diagnostic Bronchoscopy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Scheduled for flexible diagnostic bronchoscopy~* Adult patients aged 18 to 65 years~* American Society of Anesthesiologists (ASA) Physical Status Classification I-II~* BMI 18.5-25kg/m2~* Subjects provide informed consent~Exclusion Criteria:~* Severe airway obstruction~* Coagulation disorder~* Repeat bronchoscopy (more than 3 times)~* Severe liver and renal dysfunction~* Cardiovascular and cerebrovascular diseases~* Pregnancy~* Chronic opioid user~* Drug abusers or addicts

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Group F (Type: EXPERIMENTAL): Sedated with midazolam and fentanyl
- Group DR (Type: EXPERIMENTAL): Sedated with midazolam, dexmedetomidine and remifentanil
- Group DF (Type: EXPERIMENTAL): Sedated with midazolam, dexmedetomidine and fentanyl
- Group PR (Type: EXPERIMENTAL): Sedated with midazolam, propofol and remifentanil

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Helping HIV Infected Patients in South Africa Adhere to Drug Regimens

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* HIV infected~* Viral load greater than 1000 copies/ml~* CD4 count of 200 cells/mm3 or less, or World Health Organization Stage 4 disease~* Living in the area of the study site~* Had a known address for more than 3 months~* Willing to nominate a treatment supervisor (a close family member, sexual partner, friend, or community volunteer) to observe daily ingestion of tablets~* Willing to disclose HIV status to a treatment supervisor and ready to commit to long-term antiretroviral therapy~* Acceptable methods of contraception~Exclusion Criteria:~* Pregnant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Use of a patient nominated peer supporter who will observe the morning dose of ARVs
- 2 (Type: NO_INTERVENTION): Self administration of ARVs

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Trial of OnabotulinumtoxinA for Depression in Parkinson Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent is obtained in the English language;~* They are a 18 to 95 years old;~* They meet United Kingdom Brain Bank Criteria for probable idiopathic Parkinson disease;~* They meet Diagnostic and Statistical Manual (DSM)-IV criteria for major depressive disorder (MDD) as diagnosed by the M.I.N.I. at screening;~* They are judged by the investigator to have the capacity to understand the nature of the study;~* They are willing to comply with all the requirements of the study;~* They are considered by the investigator to be likely to adhere to the protocol.~Exclusion Criteria:~* They have been treated with onabotulinumtoxinA injected into the facial muscles for any reason in the 3 months prior to screening;~* They have Bipolar Disorder, Post-Traumatic Stress Disorder, a Psychotic Disorder or any other non-unipolar depressive disorder as a principal diagnosis in the 6 months prior to screening;~* They endorse active suicidal ideation at enrollment or during any study visit, or have attempted suicide in the six months prior to screening;~* They have a history of substance abuse or dependence in the 2 months prior to screening;~* They test positive for illicit drugs on urine screen, and this has not been adequately explained to the satisfaction of the investigator~* They are considered to be at significant risk of committing homicide;~* They have an unstable medical condition;~* Women of childbearing potential who are pregnant or are considering becoming pregnant during the length of the study;~* There has been a change in their PD medication or psychotherapy treatment regimen in the 30 days preceding screening;~* They are regarded, for any reason, by the principal investigator as being an unsuitable candidate for the protocol.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 95 Years
- Healthy Volunteers: f

Study Arms:
- Intervention (Type: EXPERIMENTAL): One injection of onabotulinumtoxinA (29 units for women and 40 units for men) will be injected into two facial muscles - the corrugator and procerus.
- Control (Type: PLACEBO_COMPARATOR): One injection of saline solution will be injected into two facial muscles - the corrugator and procerus.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Assessment of Utility of accelerateIQ in the Care of Patients Participating in a Pulmonary Rehabilitation Program

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male or female, at least 40 years of age;~* Diagnosis of Chronic Obstructive Pulmonary Disease (COPD);~* Enrolled in the study site's 12-week pulmonary rehabilitation program;~* Capable of completing a 6-minute walk test;~* Willing and able to comply with scheduled protocol procedures and follow up;~* Signed and dated informed consent and HIPAA materials indicating that the patient has agreed to participate in this study and has been informed of all pertinent aspects of the trial.~Exclusion Criteria:~* Patient has cognitive or physical limitations that, in the opinion of the investigator, limit the patient's ability to utilize the System as instructed;~* Patient is actively enrolled in another clinical investigation that, in the opinion of the investigator, interferes with or compromises either that patient's ability to participation in this study or the ability for the study to generate results;~* Patients who have implanted defibrillators or pacemakers;~* Patient is allergic to hydrocolloid adhesive;~* Patient does not speak English.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Propranolol in Treating Hypoglycemia Unawareness

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with Type 1 diabetes mellitus for more than 5 years with impaired awareness of hypoglycemia~* Age between 21 to 59 years old~* Hemoglobin A1c ≤ 9%; most recent value within 3 months~* No beta-blocker use history in the last 6 months~* Able to provide informed consent and willing to sign an approved consent form that conforms to federal and institutional guidelines~Exclusion Criteria:~* History of coronary, cerebral or peripheral vascular disease~* History of cardiac conduction abnormality or heart failure~* History of advanced liver disease~* Active malignancy~* Major Central or Peripheral Nervous System disease~* History of human immunodeficiency virus infection~* Contraindication to beta-blockers, including hypersensitivity to beta-blocker and bronchospastic disease~* Female in pregnancy or not able to practice effective contraception during the study period~* Concomitant acetaminophen use~* Currently utilizing unblinded real-time continuous glucose monitoring~* Advanced diabetic microvascular complications including retinopathy, neuropathy and nephropathy~* Inability to understand or cooperate with study procedure, including performing glucometer glucose assessment a minimum of four times a day, carrying glucose tablets and following standardized hypoglycemia treatment, completing hypoglycemia diary, wearing continuous glucose monitoring, and using a single glucometer~* Recent or current use or involvement in clinical studies of other therapies (e.g. opioid antagonist, SSRI, behavioral modification, relaxation of glycemic control) that may improve hypoglycemia awareness or prevent impaired hypoglycemia awareness development

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 59 Years
- Healthy Volunteers: f

Study Arms:
- Propranolol (Type: EXPERIMENTAL): After enrollment and the initial two-week continuous glucose monitoring assessment, study subjects randomized to the Propranolol Arm will be treated with Propranolol 80 Mg Oral Capsule, Extended Release daily for four weeks.
- Placebo (Type: EXPERIMENTAL): After enrollment and the initial two-week continuous glucose monitoring assessment, study subjects randomized to the Placebo Arm will be treated with matching placebo oral capsule daily for four weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Protocol to Obtain Blood and Bone Marrow Samples for Myeloma Research

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Participant population is multiple myeloma patients over the age of 18 who are undergoing a scheduled bone marrow collection and/or blood drawing procedure as part of their routine treatment or follow up, and healthy volunteers over the age of 18 who have agreed to have a bone marrow and/or blood harvest as part of a donation to a transplant recipient.~Exclusion Criteria:~* Patients, who in the opinion of their physician, would be adversely affected by removal of an extra15ml of blood and /or an extra 10ml of bone marrow.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Healthy Volunteers (Type: None): Healthy volunteers who have agreed to have a bone marrow and/or blood harvest as part of a donation to a transplant recipient.
- Patients with multiple myeloma (Type: None): Patients undergoing routine blood draw and bone marrow aspirates as part of their ongoing follow-up care for myeloma at the Norris Cotton Cancer Center of DHMC.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Anal Incontinence With Intersphincteric Implants

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Subject has been informed of the nature of the study, agrees to its provisions, and has provided written informed consent.~2. Subject must be at least 18 years of age~3. Subject must have a St Marks score of at least 11~4. Subject must be able to comply with study and study follow-up requirements.~Exclusion Criteria:~1. Subjects with Crohn's disease or Ulcerative colitis~2. Subject has (a history of) malignancy in the rectum or anal canal~3. Subject has an ongoing treatment with chemotherapy (all indications)~4. Subject has verified active anal fistula(e)~5. Subject is unable or unwilling to provide informed consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intersphincteric implants (Type: EXPERIMENTAL): Treatment with intersphincteric implants in the anal sphincter using Sphinkeeper

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy